Ascletis Pharmaceuticals

Acne
Biotech

Ascletis prepares for China regulators after acne pill ph. 3 win

The Chinese biotech claimed the Sagimet Biosciences-sourced drug can hold its own against Seysara and doxycycline.
James Waldron Jun 4, 2025 5:08am
reshuffle pipeline target reorganize shift change

Ascletis pulls FXR agonist from pipeline over phase 2 data

Apr 3, 2024 8:50am